3rd generation glp 1 agonist GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease LY3437943, a novel triple glucagon,

People who already have GLP-1 drugs covered through their Medicare Part D plan or have Type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease are not eligible

An area of interest for GLP-1 agents is their potential use in treating polycystic ovarian syndrome (PCOS)

Exposure to toxins can increase oxidative stress, leading to a decline in glutathione levels

That means you can experience the benefits of glutathione without even leaving your home

Whether you're considering Wegovy, Zepbound, Ozempic, Mounjaro, bariatric surgery, or the Medicare GLP-1 Bridge Program, our insurance specialists are here to help you understand your coverage before treatment begins